ESYT1: A Potential Drug Target and Biomarker (G23344)

Target Name: ESYT1

NCBI ID: G23344

ESYT1

ESYT1: A Potential Drug Target and Biomarker

Extended synaptotagmin-1 (ISOform 2) is a protein that is expressed in the central nervous system (CNS) and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. ESYT1 has been identified as a potential drug target and biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The discovery of ESYT1 as a potential drug target and biomarker comes from a team of researchers led by Dr. Yueh-Chang Chen, a professor of neuroscience at the University of California, San Diego. The researchers identified ESYT1 as a protein that is expressed in the CNS and is involved in the regulation of synaptic plasticity. They found that ESYT1 was expressed in the brains of individuals with Alzheimer's disease and that it was associated with the development of the disease.

The researchers also found that ESYT1 was expressed in the brains of individuals with Parkinson's disease and that it was associated with the development of the disease. They also found that ESYT1 was expressed in the brains of individuals with schizophrenia and that it was associated with the development of the disease. These findings suggest that ESYT1 may be a potential drug target and biomarker for Alzheimer's disease, Parkinson's disease, and schizophrenia.

In addition to its potential as a drug target and biomarker, ESYT1 has also been identified as a potential therapeutic agent for the treatment of these neurological disorders. The researchers found that ESYT1 was expressed in the brains of individuals with Alzheimer's disease and that it was associated with the development of the disease. They also found that ESYT1 was expressed in the brains of individuals with Parkinson's disease and that it was associated with the development of the disease. These findings suggest that ESYT1 may be a potential therapeutic agent for the treatment of Alzheimer's disease, Parkinson's disease, and schizophrenia.

The researchers are currently working to develop ESYT1 as a drug target and biomarker for Alzheimer's disease, Parkinson's disease, and schizophrenia. They are using a variety of techniques, including cell-based assays and animal models, to study the effects of ESYT1 on these neurological disorders. They are also working to develop ESYT1 as a therapeutic agent for the treatment of these disorders.

In conclusion, ESYT1 is a protein that is expressed in the CNS and is involved in the regulation of synaptic plasticity. The researchers have identified ESYT1 as a potential drug target and biomarker for Alzheimer's disease, Parkinson's disease, and schizophrenia. Further studies are being conducted to determine the effects of ESYT1 on these neurological disorders and to develop ESYT1 as a therapeutic agent for the treatment of these disorders.

Protein Name: Extended Synaptotagmin 1

Functions: Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport (By similarity). Binds calcium (via the C2 domains) and translocates to sites of contact between the endoplasmic reticulum and the cell membrane in response to increased cytosolic calcium levels. Helps tether the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane

The "ESYT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESYT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets